 |
|
|
| |
Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients
|
| |
| |
Reported by Jules Levin
Glasgow 2018, Oct 27-31
Scott Letendre,1Anthony Mills,2Debbie Hagins,3Susan Swindells,4Franco Felizarta,5Jerome DeVente,6Christopher Bettacchi,7Yu Lou,8 Susan Ford,9Annie Cameron,9Kenneth Sutton,10Jafar Sadik Shaik,11Herta Crauwels,12Ronald D'Amico,10Parul Patel10
1UCSD Antiviral Research Center, San Diego, CA, USA; 2Mills Clinical Research, Los Angeles, CA, USA; 3Chatham County Health Department, Savannah, GA, USA; 4University of Nebraska Medical Center, Omaha, NE, USA; 5Office of Franco Felizarta, MD, Bakersfield, CA, USA; 6Long Beach Education and Research Consultants, Long Beach, CA, USA; 7North Texas Infectious Diseases Consultants, P.A., Dallas, TX, USA; 8PAREXEL International, Durham, NC, USA; 9GlaxoSmithKline, Research Triangle Park, NC, USA; 10ViiV Healthcare, Research Triangle Park, NC, USA; 11GlaxoSmithKline, Collegeville, PA, USA; 12Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
